Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMD112
- Development stage
- Preclinical
- Lead developer
- Holy Stone Healthcare
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Topical, Ophthalmic
01
Overview
AMD112 is a preclinical-stage hyaluronic acid (HA)-conjugated small molecule therapy being developed by Holy Stone Healthcare for the treatment of wet age-related macular degeneration (wAMD) and other neovascular retinal diseases. Developed using the proprietary HylRetinX™ platform, AMD112 is designed for non-invasive delivery across the blood-retinal barrier via oral or topical (eyedrop) administration. The drug utilizes CD44-mediated targeting through its HA conjugation to deliver a small molecule payload that modulates Vascular Endothelial Growth Factor (VEGF) activity. By inhibiting pathological neovascularization in the retina through a non-invasive route, AMD112 aims to provide a patient-friendly alternative to the current standard of care, which typically requires frequent intravitreal injections.
- Other names
- HylRetinX
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on AMD112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMD112.